1. All
  2. Commentary
  3. Headlines

    Related Topics:

    1. Nvidia Reports In-Line 1Q Results, 2Q Guidance Echoes Expected Woes in PC Market


      Fri, 8 May 2015

      business grew 5% from the same period last year, mainly due to strong sales in PC gaming, including high-end Maxwell-based GTX GPUs. We think Nvidia's products in the gaming segment exhibit sustainable differentiation, primarily in its high-end standalone

    2. Nvidia Highlights Promising Avenues for Growth During Investor Day; Shares Slightly Overvalued


      Thu, 19 Mar 2015

      products, but the one that caught our attention was the latest and greatest high-end graphics processing unit, the GeForce GTX Titan X. At a hefty $999 price point, Nvidia's premium video card is specifically tailored to the gaming enthusiast market

    3. How’s the Market Feeling These Days?


      Thu, 16 Oct 2014

      GTx GTXI announced Thursday that the Data Safety Monitoring Board has ..... s composition of matter patent may expire around the time GTx expects an FDA approval in 2009. After that, GTx may need to rely on weak patents for market exclusivity.

    4. When Flexibility Meets Opportunity in the European Commercial Real Estate Market


      Wed, 13 Nov 2013

      We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.

    5. America: The New Europe?


      Wed, 2 Oct 2013

      GTx adds a European partner.

    6. GTx muscle drug fails late-stage trials, shares plunge


      Mon, 19 Aug 2013

      (Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...

    7. Dropping Coverage of GTx


      Sun, 24 Oct 2010

      We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.

    8. Drug Development Moves Along at GTx


      Fri, 17 Sep 2010

      GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to

    9. Disappointing Results for GTx


      Wed, 26 May 2010

      GTx GTXI reported disappointing results in its Phase III trial for Acapodene for the ..... study protocol and demands a larger or more expensive trial that rises above GTx and partner Ipsen's preset funding threshold for a second trial . Then the

    10. GTx , Ipsen Expand Deal


      Tue, 23 Mar 2010

      GTx GTXI announced Tuesday that it has expanded its deal with European partner Ipsen . Ipsen will pay GTx about $ 58 million in milestones for a second ..... European approval . This deal will improve GTx 's near - term cash reserves and help it

    « Prev123Next »
    Content Partners